GlassScriptPhysician profile
Miguel L Hizon
NPI 1730184086
$16,546.46
in general payments reported to CMS, 2019-2025
41 companies · $2,604 in 2025
The $2,604 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,521 · 2020: $1,294 · 2021: $2,221 · 2022: $2,578 · 2023: $2,339 · 2024: $2,990 · 2025: $2,604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,458 · Education: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,457.61 |
| Education | $475.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,767.01 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Opko Pharmaceuticals, LLC | $1,748.65 | 2019-2025 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $1,546.20 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $1,331.76 | 2020-2025 | Acthar |
| Vifor Pharma, INC. | $1,171.64 | 2019-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $1,016.15 | 2019-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $1,003.58 | 2019-2025 | |
| Glaxosmithkline, LLC. | $688.21 | 2021-2024 | Benlysta, Bexsero, Jesduvroq |
| Novo Nordisk INC | $667.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Akebia Therapeutics INC | $598.26 | 2019-2025 | Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $562.19 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $495.29 | 2019-2025 | Jardiance |
| Horizon Therapeutics Plc | $474.60 | 2021-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $467.73 | 2019-2025 | |
| Ardelyx, INC. | $355.60 | 2024-2025 | Ibsrela |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miguel Hizon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.